NCT03870490View on ClinicalTrials.gov

Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Healthy Subjects
Interventions
DRUG

VNRX-5133 + cefepime

IV infusion (3 doses)

Trial Locations (1)

06102

Hartford Hospital, Hartford

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Venatorx Pharmaceuticals, Inc.

INDUSTRY

NCT03870490 - Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects | Biotech Hunter | Biotech Hunter